Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
VIVUS Confirms QSIVA® Price Reduction Is Now Effective Across Nordics and Poland
GlobeNewswire, Inc.
— The lowered pricing structure is now available for 963,88 SEK per bottle at pharmacies throughout Sweden AMSTERDAM, March 18, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the development...
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
GlobeNewswire, Inc.
ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300...
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
GlobeNewswire, Inc.
REYKJAVIK, Iceland, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached a...
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
GlobeNewswire, Inc.
Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kuppermann, M.D., Ph.D. New post-hoc analysis of OCT...
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
GlobeNewswire, Inc.
— The new pricing structure is made available as of February for 566,13 ISK per day at pharmacies throughout Iceland AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the...
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
GlobeNewswire, Inc.
REYKJAVIK, Iceland, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into...
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
GlobeNewswire, Inc.
ZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology,...
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
GlobeNewswire, Inc.
— The new pricing structure is made available as of February for 26,63 DKK per day at pharmacies throughout Denmark AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the...
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
GlobeNewswire, Inc.
— The new pricing structure is made available as of February for 3.39 EUR per day at pharmacies throughout Finland AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the...
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
GlobeNewswire, Inc.
— The new pricing structure is made available as of February for 32,13 SEK per day at pharmacies throughout Sweden AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the...
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
GlobeNewswire, Inc.
Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) management Oculis is on track to report topline results in June 2026 from DIAMOND Phase 3...
Why the Radiopharmaceutical CDMO Market is a Smart Investment: USD 8.50 Bn by 2035
GlobeNewswire, Inc.
Ottawa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The radiopharmaceutical CDMO market is driven by rising nuclear medicine use, growing outsourcing of radiopharmaceutical development, and demand for compliant, end-to-end manufacturing solutions.
Vanta and Carahsoft Announce Vanta’s Achievement of FedRAMP® 20x Class C Certification
GlobeNewswire, Inc.
SAN FRANCISCO and RESTON, Va., July 09, 2026 (GLOBE NEWSWIRE) -- Vanta, the Agentic Trust Platform, and Carahsoft Technology Corp., The Trusted Government IT Solutions Provider®, today announced that Vanta has achieved Federal Risk and...
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
GlobeNewswire, Inc.
Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2...
Oculis to Participate in Upcoming Investor Conferences
GlobeNewswire, Inc.
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with...
Oculis Publishes Invitation to the Annual General Meeting
GlobeNewswire, Inc.
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300...
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
GlobeNewswire, Inc.
REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug...
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
GlobeNewswire, Inc.
REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and...
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
GlobeNewswire, Inc.
Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026 A non-invasive topical treatment for diabetic macular edema (DME) has the potential to address significant...
MAPS Celebrates 40 Years at a Defining Moment for Psychedelics
GlobeNewswire, Inc.
Founded in April 1986 to advance psychedelic research and knowledge, MAPS has raised more than $150 million, supported 45 studies, and shaped the global policy and cultural landscape of psychedelics.
Sign up for:
Iceland Health Focus
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.